HIV CLIN TRIALS 润色咨询

HIV CLINICAL TRIALS

出版年份：2000 年文章数：暂无数据 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：1.2% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1091144, encodeId=d4a1109114469, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091143, encodeId=994c10911436a, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799514, encodeId=32dbe99514f8, content=改名了！！现在叫HIV Research & Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 23 23:20:45 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497447, encodeId=e6bb49e447b0, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=)]
    2021-12-28 桑晒麦拉

    我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1091144, encodeId=d4a1109114469, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091143, encodeId=994c10911436a, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799514, encodeId=32dbe99514f8, content=改名了！！现在叫HIV Research & Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 23 23:20:45 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497447, encodeId=e6bb49e447b0, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=)]
    2021-12-27 学医的彭于晏

    每个期刊梯度一般情况下选择几个备选期刊合适？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1091144, encodeId=d4a1109114469, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091143, encodeId=994c10911436a, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799514, encodeId=32dbe99514f8, content=改名了！！现在叫HIV Research & Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 23 23:20:45 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497447, encodeId=e6bb49e447b0, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=)]
    2020-06-23 lovetcm

    改名了！！现在叫HIV Research & Clinical Practice

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1091144, encodeId=d4a1109114469, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091143, encodeId=994c10911436a, content=每个期刊梯度一般情况下选择几个备选期刊合适？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799514, encodeId=32dbe99514f8, content=改名了！！现在叫HIV Research & Clinical Practice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 23 23:20:45 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=497447, encodeId=e6bb49e447b0, content=跨过2分了，明年会不会再略冲冲，很有希望, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pingjian888, createdTime=Mon Jul 01 11:36:00 CST 2013, time=2013-07-01, status=1, ipAttribution=)]
    2013-07-01 pingjian888

    跨过2分了，明年会不会再略冲冲，很有希望

    0

共6条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分